Overall survival in patients with glioblastoma before and after bevacizumab approval
Sign Up to like & getrecommendations! Published in 2018 at "Current Medical Research and Opinion"
DOI: 10.1080/03007995.2017.1392294
Abstract: Abstract Objective: Glioblastoma (GBM) is an aggressive disease with limited therapeutic options. While bevacizumab was approved in 2009 for the treatment of patients with progressive GBM, its impact on overall survival (OS) remains unclear. Using… read more here.
Keywords: survival; bevacizumab approval; 2006 2008; overall survival ... See more keywords